Iannone Robert, EVP, GHR, D, CMO, reported an open-market or private sale at Jazz Pharmaceuticals plc involving 11423.000000 shares for an estimated $2840516.29. Reported holdings after the transaction were 112997.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
EVP, Global Head of R&D & CMO
This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred…
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $247.29 to $248.24. The price reported reflects the weighted average sale price. The Reporting Person hereby…
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $248.29 to $249.24. The price reported reflects the weighted average sale price. The Reporting Person hereby…
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $249.33 to $250.325 The price reported reflects the weighted average sale price. The Reporting Person hereby…
Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $250.33 to $251.29. The price reported reflects the weighted average sale price. The Reporting Person here…
Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $251.37 to $252.31. The price reported reflects the weighted average sale price. The Reporting Person here…
These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1…
These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of May 29,…
0 other filings
0 recent txs